Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced that an article entitled "Pivotal Trial with Plant-Cell-Expressed Recombinant Glucocerebrosidase, taliglucerase alfa, a Novel Enzyme Replacement Therapy for Gaucher Disease" has been published in Blood, the Journal of the...